Back

Rosen Law Firm investigates Disc Medicine after 22% stock drop on FDA decision

Verifying
  • Rosen Law Firm investigates potential securities claims involving Disc Medicine shareholders.
  • 22%: Disc Medicine shares fell on February 13, 2026.
  • FDA issued a Complete Response Letter concerning Disc Medicine’s bitopertin program.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.